Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Pharming Group (PHAR) Stock Forecast & Price Target

Pharming Group logo
$12.66 -0.22 (-1.67%)
As of 01:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pharming Group - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
1
Buy
3

Based on 5 Wall Street analysts who have issued ratings for Pharming Group in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 1 has given a sell rating, 1 has given a hold rating, and 3 have given a buy rating for PHAR.

Consensus Price Target

$38.33
202.91% Upside
According to the 5 analysts' twelve-month price targets for Pharming Group, the average price target is $38.33. The highest price target for PHAR is $41.00, while the lowest price target for PHAR is $37.00. The average price target represents a forecasted upside of 202.91% from the current price of $12.66.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for PHAR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pharming Group and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PHAR Analyst Ratings Over Time

TypeCurrent Forecast
5/21/25 to 5/21/26
1 Month Ago
4/21/25 to 4/21/26
3 Months Ago
2/20/25 to 2/20/26
1 Year Ago
5/21/24 to 5/21/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$38.33$38.33$38.00$30.00
Forecasted Upside202.91% Upside123.57% Upside132.27% Upside185.99% Upside
Consensus RatingHoldHoldModerate BuyBuy

PHAR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PHAR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pharming Group Stock vs. The Competition

TypePharming GroupMedical CompaniesBroader Market
Consensus Rating Score
2.40
2.29
2.52
Consensus RatingHoldHoldModerate Buy
Predicted Upside197.85% Upside1,726.20% Upside16.44% Upside
News Sentiment Rating
Neutral News

See Recent PHAR News
Neutral News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
5/11/2026 DowngradeHold (C-)Sell (D)
4/10/2026 UpgradeStrong SellHold
4/10/2026
Whitney Ijem
4 of 5 stars
Initiated CoverageBuy$37.00+117.90%
3/24/2026Reiterated RatingBuy$37.00+130.04%
3/13/2026Reiterated RatingOutperform$42.00 ➝ $41.00+176.47%
12/9/2024 Initiated CoverageBuy$14.00+81.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:52 PM ET.


PHAR Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Pharming Group is $38.33, with a high forecast of $41.00 and a low forecast of $37.00.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pharming Group in the last twelve months. There is currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PHAR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PHAR, but not buy additional shares or sell existing shares.

According to analysts, Pharming Group's stock has a predicted upside of 202.91% based on their 12-month stock forecasts.

Over the previous 90 days, Pharming Group's stock had 4 downgrades and 3 upgrades by analysts.

Pharming Group has been rated by research analysts at Canaccord Genuity Group, HC Wainwright, Oppenheimer, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Pharming Group more than other "medical" companies. The consensus rating score for Pharming Group is 2.40 while the average consensus rating score for "medical" companies is 2.30. Learn more on how PHAR compares to other companies.


This page (NASDAQ:PHAR) was last updated on 5/21/2026 by MarketBeat.com Staff.
From Our Partners